
Take Solutions Analyst Review May 2026
Updated: 27 May 2026 • 3:44 pm
Posted by:

This Take Solutions analyst review for May 2026 covers all critical data investors need for TAKE at Rs 29.63. Take Solutions is a technology company for life sciences and supply chain. This Take Solutions analyst review analyses technical levels, business fundamentals, valuation, and key risks for TAKE through FY27.
Click Here – Get Free Investment Predictions
Take Solutions Analyst Review: Company Snapshot May 2026
Take Solutions provides regulatory affairs, pharmacovigilance, and clinical data management IT solutions to global pharma companies. The table below summarises key metrics for this Take Solutions analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | TAKE |
| Sector | IT Services – Life Sciences Tech |
| CMP (May 2026) | Rs 29.63 |
| 52 Week High | Rs 31.11 |
| 52 Week Low | Rs 28.15 |
| Market Cap | Rs 1,200 Crore |
| Trailing P/E | NAx |
| Analyst Consensus Target | Rs 37.04 |
| Bull Case Target | Rs 45.93 |
| Bear Case Target | Rs 25.19 |
Analyst Insight: Take Solutions Analyst Review for FY27
Associate Director Kunal Singla suggests watching Take Solutions closely in May 2026. At Rs 29.63, Kunal Singla flags IT Services – Life Sciences Tech sector dynamics as the key driver for TAKE’s price action. Support is near Rs 28.71 and resistance near Rs 31.41. Kunal Singla’s perspective in this Take Solutions analyst review is not a buy recommendation.
Technical Analysis in This Take Solutions Analyst Review
This Take Solutions analyst review places TAKE at Rs 29.63 within its 52-week band of Rs 28.15 to Rs 31.11. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating TAKE.
The Take Solutions analyst review identifies support in the Rs 28.71 to Rs 28.15 range and resistance in the Rs 31.41 to Rs 33.34 zone. A sustained close above Rs 31.41 could signal momentum toward the analyst consensus target of Rs 37.04.
Screen the best stocks on the Univest Screener.
Support and Resistance in This Take Solutions Analyst Review
- Support Zone: Rs 28.71 to Rs 28.15 – this Take Solutions analyst review identifies this as a potential accumulation signal for TAKE.
- Resistance Zone: Rs 31.41 to Rs 33.34 – the Take Solutions analyst review flags a close above Rs 31.41 as a positive signal for TAKE.
- Consensus Target: Rs 37.04 is the base-case target in this Take Solutions analyst review.
Business Segments in This Take Solutions Analyst Review
Life Sciences Regulatory Technology
This primary segment drives revenue and margin for Take Solutions, supporting the earnings trajectory toward Rs 37.04 in this Take Solutions analyst review.
Clinical Data and Pharmacovigilance Software
This segment adds meaningful scale to Take Solutions’s model and is a key EPS contributor through FY27 as identified in this Take Solutions analyst review.
Supply Chain Technology Solutions
This growth frontier is a potential re-rating catalyst for TAKE and a key element of this Take Solutions analyst review.
Valuation: Take Solutions Analyst Review Bull Bear Base Case
At Rs 29.63 and P/E of NAx, this Take Solutions analyst review sets three scenarios: bull case Rs 45.93, base case Rs 37.04, and bear case Rs 25.19.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 45.93 | Strong FY27 delivery and IT Services – Life Sciences Tech re-rating |
| Base Case | Rs 37.04 | Moderate growth per analyst consensus in this Take Solutions analyst review |
| Bear Case | Rs 25.19 | Earnings miss or macro headwinds for TAKE |
FY27 Outlook in This Take Solutions Analyst Review
This Take Solutions analyst review for FY27 is constructive provided TAKE delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor IT Services – Life Sciences Tech indicators, RBI policy, and FII flow trends.
Key Risks in This Take Solutions Analyst Review
This Take Solutions analyst review identifies four key risks for TAKE: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment. This Take Solutions analyst review is for educational purposes only.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Take Solutions Analyst Review Verdict May 2026
This Take Solutions analyst review concludes that TAKE at Rs 29.63 presents a defined risk-reward with consensus target Rs 37.04. The 52-week range of Rs 28.15 to Rs 31.11 provides further context. Use this Take Solutions analyst review as a research reference and consult a SEBI-registered advisor before investing in TAKE.
FAQs: Take Solutions Analyst Review 2026
What is the analyst target for Take Solutions in 2026?
The Take Solutions analyst review consensus target is Rs 37.04, bull case Rs 45.93, bear case Rs 25.19.
Is Take Solutions a good buy at Rs 29.63?
At Rs 29.63 with PE NAx and target Rs 37.04, this Take Solutions analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Take Solutions analyst review.
What is the 52-week high and low of Take Solutions?
52-week high is Rs 31.11 and 52-week low is Rs 28.15. This Take Solutions analyst review contextualises TAKE at Rs 29.63 within this range.
What are the key risks for Take Solutions?
Key risks in this Take Solutions analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the IT Services – Life Sciences Tech sector.
Where can I track live data for Take Solutions?
Track Take Solutions’s live price on the Univest Screener to complement this Take Solutions analyst review with real-time data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
Recent Articles
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Triveni Turbine Share Price Today: Should You Buy or Not?
Markolines Pavement Technologies Q4 FY26 Results: PAT Rs 11 Cr
Grauer and Weil India Q4 FY26 Results: PAT Rs 50 Cr
Paramount Communications Share Price Today: Should You Buy or Not?
NMDC Ltd Share Price Today: Should You Buy or Not?
Popular this week
Triveni Turbine Share Price Today: Should You Buy or Not?
Markolines Pavement Technologies Q4 FY26 Results: PAT Rs 11 Cr
Grauer and Weil India Q4 FY26 Results: PAT Rs 50 Cr
Paramount Communications Share Price Today: Should You Buy or Not?
NMDC Ltd Share Price Today: Should You Buy or Not?

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas





